Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FM3HV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $71,174
Award facts
- Contract value 100% obligated
- $71,173.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $71,173.83 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on January 28, 2026, with completion expected by January 29, 2026. This firm fixed-price, non-set-aside contract represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, designated SPE2DX and valued at $999.9 million through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location and deliver this specialty medication to support military healthcare programs. Dupixent is a biologic treatment commonly prescribed for eczema, asthma, and other inflammatory conditions, making this procurement consistent with DLA's mandate to supply critical pharmaceuticals across the federal healthcare system.
AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc., which serves as the parent organization and holds the underlying IDC vehicle with DLA. The company's extensive portfolio of federal pharmaceutical contracts demonstrates its capability to meet competitive procurement requirements for specialized medical commodities. This delivery order exemplifies the operational efficiency of DLA's pharmaceutical prime vendor model, enabling rapid task order issuance for essential medications needed by military treatment facilities and other Defense Health Agency beneficiaries worldwide. The non-set-aside status reflects open competition in the pharmaceutical supply market for this critical defense medical supply chain requirement.
Quick answers
Who was awarded contract SPE2DR26FM3HV?
SPE2DR26FM3HV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FM3HV worth?
The government has obligated $71,174 on SPE2DR26FM3HV.
Is contract SPE2DR26FM3HV an order under another contract?
Yes. SPE2DR26FM3HV is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM3HV competed?
The extent of competition for SPE2DR26FM3HV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award